Kalchev Emilian
Diagnostic Imaging, St Marina University Hospital, Varna, BGR.
Cureus. 2023 Jul 4;15(7):e41369. doi: 10.7759/cureus.41369. eCollection 2023 Jul.
Objective This study aimed to explore the potential of prostate-specific antigen density (PSAD) as a supplementary tool for defining high-risk Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions in the peripheral zone on non-contrast-enhanced MRI. This additional stratification tool could supplement the decision-making process for biopsy, potentially helping in identifying higher-risk patients more accurately, minimizing unnecessary procedures in lower-risk patients, and limiting the need for dynamic contrast-enhanced (DCE) scans. Materials and methods Between January 2019 and April 2023, 30 patients with PI-RADS 3 lesions underwent MRI-ultrasound fusion biopsies at our institution. Age and PSAD values were investigated using logistic regression and chi-square automatic interaction detection (CHAID) analysis to discern their predictive value for malignancy. Results The mean patient age was 64.7 years, and the mean PSAD was 0.13 ng/mL. Logistic regression demonstrated PSAD to be a significant predictor of cancer (p=0.012), but not age (p=0.855). CHAID analysis further identified a PSAD cut-off value of 0.12, below which the cancer detection rate was 23.1% and above which the rate increased to 76.5%. Conclusions This exploratory study suggests that PSAD might be utilized to enhance the stratification of high-risk PI-RADS 3 lesions in the peripheral zone on non-contrast-enhanced MRI, aiding in decision-making for biopsy. While biopsy remains the gold standard for definitive diagnosis, a high PSAD value may suggest a greater need for biopsy in this specific group. Although further validation in larger cohorts is required, our findings contribute to the ongoing discourse on optimizing PI-RADS 3 lesion management. Limitations include a small sample size, the retrospective nature of the study, and the single-center setting, which may impact the generalizability of our results.
目的 本研究旨在探讨前列腺特异性抗原密度(PSAD)作为一种辅助工具,用于在非增强MRI上定义外周带中高危前列腺影像报告和数据系统(PI-RADS)3类病变的潜力。这种额外的分层工具可以辅助活检的决策过程,可能有助于更准确地识别高危患者,减少低危患者的不必要检查,并减少动态对比增强(DCE)扫描的需求。
材料与方法 2019年1月至2023年4月期间,30例PI-RADS 3类病变患者在我院接受了MRI-超声融合活检。使用逻辑回归和卡方自动交互检测(CHAID)分析研究年龄和PSAD值,以辨别它们对恶性肿瘤的预测价值。
结果 患者的平均年龄为64.7岁,平均PSAD为0.13 ng/mL。逻辑回归显示PSAD是癌症的显著预测因子(p=0.012),但年龄不是(p=0.855)。CHAID分析进一步确定PSAD的临界值为0.12,低于该值时癌症检出率为23.1%,高于该值时检出率增至76.5%。
结论 这项探索性研究表明,PSAD可用于加强非增强MRI上外周带高危PI-RADS 3类病变的分层,辅助活检决策。虽然活检仍然是明确诊断的金标准,但高PSAD值可能表明该特定组患者更需要活检。尽管需要在更大的队列中进行进一步验证,但我们的研究结果有助于正在进行的关于优化PI-RADS 3类病变管理的讨论。局限性包括样本量小、研究的回顾性性质以及单中心设置,这可能会影响我们结果的普遍性。